Brief: Chosa Oncology AB Publishes Results From Clinical Phase 2 Trial Of Liposomal Formulation In Breast Cancer, Using Predictive Marker For Cisplatin
03/06/2023 14:20
Chosa Oncology AB CHOSA.TE :
* CHOSA ONCOLOGY AB PUBLISHES RESULTS FROM CLINICAL PHASE 2
TRIAL
OF LIPOSOMAL FORMULATION IN BREAST CANCER, USING PREDICTIVE
MARKER FOR CISPLATIN
Source text for Eikon: ID:nWkr7g3hkw
Further company coverage: CHOSA.TE
Recent news on Chosa Oncology AB
See all newsBrief: Chosa Oncology Appoints Gerton Jönsson As New Chief Financial Officer
Brief: CHOSA Oncology AB Says Postpones Publication Of Interim Report Q4 2024
Brief: Chosa Oncology Carried Out Directed Issue Of Sek 1,55 Mln To Further Increase Business Development Activities
Brief: Chosa Oncology Announces Decision To Postpone Release Of Interim Report For Q2 2023
Brief: Chosa Oncology AB Publishes Results From Clinical Phase 2 Trial Of Liposomal Formulation In Breast Cancer, Using Predictive Marker For Cisplatin